VIVO Cannabis (TM) Announces Launch of Beacon Medical (TM) High Dose CBD Oil and Pediatric Compassionate Care Program

0

Toronto, Ontario – (Newsfile Corp. – November 23, 2021) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO“or the”Society“), a leading supplier of medical cannabis products and patient services, and licensee under the Cannabis Act through its wholly owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc., today announced the launch of its newest formulation of medical cannabis product: high-dose cannabidiol (CBD) under its Beacon Medical ™ brand.

Beacon Medical ™ 2: 100 High Dose CBD Oil is a distillate based cannabis oil containing 100 mg of CBD and less than 2 mg of tetrahydrocannabinol (THC). The entire Beacon Medical ™ oil-based product family is formulated from a non-GMO, food-grade medium chain triglyceride (MCT) carrier oil, which gives the end product a taste that is both odorless. and tasteless.

“With our commitment to the medical cannabis market, the VIVO team aspires to provide superior quality cannabinoid-based medical products to our patients, and Beacon Medical ™ CBD + | oh was launched in response to patient knowledge that our team has gathered over time, ”commented Ray Laflamme, Co-Founder of Canna Farms and CEO of VIVO. “We recognize that many of our patients are looking for products that meet their individualized needs, and this latest addition to the Beacon Medical product family is a great high potency CBD option for patients and it will be available to patients, physicians. and hospitals. “

CBD tag + | O [2:100] Extra Strength CBD Oil To Help Patients Achieve Their Health Goals

To view an improved version of this graphic, please visit:
https://orders.newsfilecorp.com/files/3063/104861_d6d7d616944e29cd_002full.jpg

VIVO simultaneously announced the launch of a Pediatric Compassionate Care Program to support caregivers and families in need of medical cannabis to treat a variety of pediatric conditions. Eligible patients will receive substantial discounts on all Beacon Medical ™, Canna Farms ™, Fireside ™ and Lumina ™ CBD products.

VIVO sets itself apart with its patient-centric approach, ensuring choice, access and constant supply to patients. Beacon Medical ™ products are available exclusively in certain medical markets in Canada, Australia and Germany.

This new Beacon Medical ™ high CBD oil is available on Canna Farms’ online medical marketplace for Canadian medical customers. Patients who need assistance with registering or placing orders can contact the VIVO Customer Service team at 1 (855) 882-0988 or [email protected]

About VIVO Cannabis ™

VIVO Cannabis ™ is recognized for its superior quality cannabis products and services. It holds production and sales licenses from Health Canada and operates world-class indoor and seasonal airhouse grow facilities. VIVO has a collection of medical, health and wellness brands, each targeting different customer segments, including Canna Farms ™, Beacon Medical ™, Fireside ™ and Lumina ™. Harvest Medicine ™, VIVO’s scalable, patient-centric network of medical cannabis clinics, has handled over 150,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com.

For more information:

VIVO Investor Relations
+1 416-848-9839
[email protected]

Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/

Forward-looking information disclaimer

Certain statements contained in this press release are forward-looking statements, that is, statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its direction regarding the future. Such statements are subject to risks and uncertainties which may cause actual results, performance or developments to differ materially from those contained in forward-looking statements. No assurance can be given that any of the events anticipated by forward-looking statements will occur or, if they occur, what benefits the Company will derive from them. Readers are urged to carefully consider these factors as well as the more detailed risk factors included in the Company’s most recent MD&A and analysis available on SEDAR, in evaluating the forward-looking statements contained in this press release. press and are cautioned not to place undue reliance on these forward-looking statements, which are qualified in their entirety by these cautions. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to publicly update these forward-looking statements, whether as a result of new information, future events or results. or otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104861



Source link

Share.

Comments are closed.